Understanding PSA Tests for Prostate Cancer: Key Benefits and Drawbacks for Midlife and Older Men

PSA Testing: Understanding its Benefits and Risks

Former President Joe Biden’s prostate cancer diagnosis has sparked renewed discussion about PSA testing. This blood test is often used to check for prostate cancer, the most commonly diagnosed cancer in men in the U.S. However, experts remind us that it’s not a foolproof method.

PSA tests measure the level of prostate-specific antigen, a protein made by both healthy and cancerous prostate cells. While high PSA levels can indicate cancer, they can also lead to false positives or find slow-growing cancers that may never pose a harm. A fascinating study revealed that over one-third of white men and half of Black men in their 70s have prostate cancers that are unlikely to affect their health.

Dr. Brent Rose, a radiation oncologist, emphasizes that while PSA screening can be useful, it’s not without drawbacks. "It can lead to unnecessary treatments with significant side effects," he said. This includes complications like impotence and incontinence.

Many experts have been debating the best approach to prostate cancer screening since PSA tests became common in the 1990s. There’s a key challenge: we want to catch aggressive cancers early without over-treating less harmful cases.

Critics point out that guidelines for PSA testing have fluctuated over the years. The U.S. Preventive Services Task Force has shifted its recommendations, advising against screening for older men while suggesting discussions for those aged 55 to 69. This inconsistency has left many confused.

Dr. Alicia Morgans from the Dana-Farber Cancer Institute believes there’s a need for better guidance. She argues that current recommendations stem from flawed studies. For example, nearly 90% of men in control groups of certain trials had at least one PSA test, muddying results. Morgans advocates for earlier screenings, especially for Black men and those with family histories.

Meanwhile, Dr. Matthew Cooperberg at UCSF is pushing for a shift in how we view early-stage prostate cancer. He believes in renaming it to reduce the stigma around the diagnosis and advocates active surveillance instead of immediate treatment for low-risk cases.

An emerging perspective in prostate cancer screening focuses on personalized approaches. Dr. Tyler Seibert suggests that, instead of rushing to biopsy after an elevated PSA, patients should consider MRIs and monitoring first. This approach allows men with low-risk cancer to live their lives without unnecessary stress and procedures.

The conversation around PSA testing is complex. Men facing decisions about screening should have discussions with their doctors, weighing the pros and cons in light of their personal health and family history. While PSA tests aren’t perfect, advancements in understanding prostate cancer could lead to better, smarter screening in the future.

For more detailed guidance on prostate cancer screening, visit the U.S. Preventive Services Task Force.

Source link